TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19467049
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment at 500 degrees C for 30 min
Study: 19467049
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment at 500 degrees C for 10 min
Study: 16461145
Drug: Wheat (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat (25 g)
Study: 16461145
Drug: Provocation dose
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provocation dose
Study: 11771000
Drug: Histamine phosphate
Normalized name: Histamine Phosphate
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine phosphate at a concentration of 4 mg/mL
Study: 7684512
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 to 1.0 microgram per day orally) plus placebo nasal spray
Study: 7684512
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg per day orally)
Study: 2963380
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of carbazochrome sodium sulfonate (AC-17)
Study: 30511966
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level laser therapy (Riancorp LTU-904)
Study: 30511966
Drug: Inactive low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive low-level laser therapy (placebo)
Study: 24959347
Drug: Steroid-free immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppressive protocol based on low-dose tacrolimus and mycophenolate mofetil (MMF) with antithymocyte globulin (ATG) induction
Study: 24959347
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive protocol based on low-dose tacrolimus, MMF, and steroids with interleukin-2 receptor (IL2-R) induction
Study: 22430565
Drug: MRI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI after surgical debridement and initiation of antibiotic therapy
Study: 20593535
Drug: gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (n = 47)
Study: 20593535
Drug: gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (n = 42)
Study: 20593535
Drug: paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 225 mg/m2 on day 1 plus carboplatin area under the curve 6.0 on day 1 (n = 49)
Study: 20593535
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy doublet regimens (overall for white and African American patients)
Study: 9244228
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg)
Study: 3100312
Drug: Etidronate 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 7.5 mg kg‐1 body weight
Study: 21160258
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for older women with high-risk breast cancer features
Study: 21160258
Drug: Surgery, endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, endocrine therapy, and radiotherapy
Study: 19670189
Drug: Tacrolimus therapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus therapy
Study: 15988077
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (diuretics, ACE inhibitors, beta-blockers, digoxin)
Study: 12717125
Drug: Pancuronium 15
Normalized name: pancuronium
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium 15 microg/kg followed by mivacurium 0.1 mg/kg
Study: 12717125
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by mivacurium 0.13 mg/kg
Study: 2058827
Drug: Fentanyl group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl group (n = 10): bolus injections of about 0.2 mg/h fentanyl and 2.5 mg/h midazolam
Study: 2058827
Drug: Ketamine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine group (n = 10): infusion of about 50 mg/h ketamine and 2.5 mg/h midazolam
Study: 6327346
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline sulphate orally
Study: 6327346
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline sulphate subcutaneously
Study: 22577718
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug and Caltrate D (600 mg/day)
Study: 22577718
Drug: Antithyroid drug,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug, Caltrate D (600 mg/day), and Alendronate (70 mg weekly)
Study: 10442322
Drug: Ossein-hydroxyapatite compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ossein-hydroxyapatite compound (OHC) 3.32 g/d
Study: 10442322
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 2.5 g/d
Study: 2359576
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home uterine activity monitoring and perinatal nursing support
Study: 26346408
Drug: TDM (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDM (therapeutic drug monitoring)
Study: 26346408
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (clinician-driven)
Study: 22974254
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (BPS) 40 µg, tid for 8 weeks
Study: 17896582
Drug: Alpha-ketoglutaric acid
Normalized name: Alpha-ketoglutaric acid
DrugBank: Oxogluric acid (DB08845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-ketoglutaric acid calcium salt (6 g AKG and 1.68 Ca/day)
Study: 14719145
Drug: Laxative group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative group (lactulose)
Study: 12439361
Drug: Fenoldopam; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam; specific agonism of dopamine‐1 receptors; details on dosage and duration not available
Study: 9625684
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg/d
Study: 7948230
Drug: Trial solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial solution (1.36% glucose and 1% peptides, 381 mOsm/kg)
Study: 7948230
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (2.27% glucose, 404 mOsm/kg)
Study: 28559862
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (EXP) - Treatment as Usual plus Cognitive Behavioral Therapy for psychosis, Family Intervention for psychosis, and Case Management.
Study: 28559862
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) - Personalized outpatient psychopharmacological treatment and non-specific supportive clinical management.
Study: 28559862
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (EXP) - Family Intervention for psychosis.
Study: 28559862
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) - No specific family intervention.
Study: 25540274
Drug: Tdap-IPV followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap-IPV followed by HepB dose 1 month later (Group 1, n = 145)
Study: 25540274
Drug: Tdap-IPV and
Normalized name: acellular pertussis vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap-IPV and HepB administered simultaneously (Group 2, n = 135)
Study: 23545612
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to the other drug after initial treatment
Study: 21762177
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered immediately after the Trier Social Stress Test (Alc0, n = 11)
Study: 21762177
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered 30 minutes after the Trier Social Stress Test (Alc30, n = 14)
Study: 21762177
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 30 minutes after the Trier Social Stress Test (Alc0 group)
Study: 21762177
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered immediately after the Trier Social Stress Test (Alc30 group)
Study: 16601576
Drug: Hydrochlorothiazide (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (alone or in combination with atenolol)
Study: 16601576
Drug: Candesartan (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (alone or in combination with felodipine)
Study: 14651725
Drug: KT3‐671 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT3‐671 40 mg
Study: 14651725
Drug: KT3‐671 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT3‐671 80 mg
Study: 14651725
Drug: KT3‐671 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT3‐671 160 mg
Study: 14651725
Drug: KT3‐671 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT3‐671 (all doses)
Study: 8733487
Drug: Tobramycin administered
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin administered eight hourly aiming for a peak concentration of 10 mg/l and trough below 2 mg/l (Group A)
Study: 8733487
Drug: Tobramycin administered
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin administered as two equal 12 hourly doses (Group B)
Study: 1444287
Drug: Didanosine 375
Normalized name: DIDANOSINE 375MG/PKG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 375 mg alone
Study: 1444287
Drug: Didanosine 375
Normalized name: DIDANOSINE 375MG/PKG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 375 mg with ranitidine 150 mg (ranitidine given 2 h prior)
Study: 1444287
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg alone
Study: 1444287
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg with didanosine 375 mg
Study: 15372199
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injection
Study: 30068305
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (saline solution)
Study: 26840904
Drug: Resistance Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Training (RT) program, twice per week for 12 weeks
Study: 22425913
Drug: Carboplatin/gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both)
Study: 19173165
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Groups B and C)
Study: 8989740
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.58 g/kg per day)
Study: 7594128
Drug: Very-low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-protein diet (0.28 g/kg per day) with ketoacid-amino acid supplement (0.28 g/kg per day)
Study: 7594128
Drug: Usual-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-protein diet (1.30 g/kg per day)
Study: 7031186
Drug: Epsilon aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epsilon aminocaproic acid (EACA), 36 g/day
Study: 7031186
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TEA), 6 g/day
Study: 29152243
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (PE) capsules for 8 weeks
Study: 25799722
Drug: Prolit super
Normalized name: Prolia
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prolit super (4 capsules daily for 2 months)
Study: 19042161
Drug: Galantamine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (24 mg/day)
Study: 12269648
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray, 128 microg once daily
Study: 2653555
Drug: Phenylpropanolamine hydrochloride
Normalized name: Phenylpropanolamine Hydrochloride
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine hydrochloride 50 mg bd (Kontexin)
Study: 2653555
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride 5 mg tid (Ditropan)
Study: 2653555
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Phenylpropanolamine and Oxybutynin)
Study: 24119227
Drug: Other immunosuppressive
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other immunosuppressive agents
Study: 21208594
Drug: TEAM intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEAM intervention (depression care management intervention focusing on optimizing antidepressant therapy through patient education, symptom monitoring, adherence promotion, and side-effect management)
Study: 9286851
Drug: mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mibefradil 100 mg once daily
Study: 9286851
Drug: diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diltiazem CD 360 mg once daily
Study: 9286851
Drug: nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine SR 40 mg twice daily
Study: 9286851
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg once daily
Study: 9286851
Drug: nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine GITS 60 mg once daily
Study: 3490807
Drug: Intermittent electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent electrical stimulation of the muscles of the legs (external electrodes), performed daily 2 X 30 min during the stimulation period (S)
Study: 20723593
Drug: Liu wei
Normalized name: Bai Liu Bark
DrugBank: Salix alba bark (DB14274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liu wei di huang wan (LDW), 12 pills, 0.2 g/pill, twice daily for 14 days
Study: 8012860
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS) 4 mg
Study: 31738150
Drug: Intradermal sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal sterile water (0.5 ml)
Study: 31738150
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.1 mg/kg plus 0.5 ml of intradermal sterile water)
Study: 27921276
Drug: Selumetinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (oral MEK inhibitor)
Study: 26155923
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (Flovent HFA)
Study: 26155923
Drug: Short acting
Normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short acting bronchodilators (Proventil HFA)
Study: 26155923
Drug: Both inhalers
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both inhalers (ICS and bronchodilators)
Study: 19808136
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil 600-mg extended-release tablets at doses of 2400, 3600, 4800, or 6000 mg
Study: 15829527
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg daily)
Study: 11345514
Drug: Cognitive orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive orientation to daily occupational performance (CO-OP)
Study: 9013720
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with carbetamide and caffeine to induce autotetraploid cells
Study: 30744491
Drug: Telerehabilitation-based motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation-based motor imagery training (Tele-MIT) twice a week for 8 weeks
Study: 30744491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (wait-list group without any additional specific treatment)
Study: 21355143
Drug: Acupuncture applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture applied to non-acupoint spots with shallow needling technique and Fluoxetine taken orally.
Study: 16750465
Drug: Amlodipine orotate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine orotate (5 mg, doubled to 10 mg QD if SiDBP >= 90 mm Hg after 4 weeks)
Study: 16750465
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate (5 mg, doubled to 10 mg QD if SiDBP >= 90 mm Hg after 4 weeks)
Study: 9158883
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg kg‐1 dolasetron mesylate (1.8 mg kg‐1 dolasetron base) by intravenous administration
Study: 9158883
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg kg‐1 dolasetron mesylate (1.8 mg kg‐1 dolasetron base) by oral administration
Study: 3619423
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral administration
Study: 8214547
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine 75 mg
Study: 2443151
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy combined with bleomycin
Study: 2443151
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy combined with a retinoid
Study: 26315564
Drug: Osteotome sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteotome sinus floor elevation (OSFE) with β‐TCP and DBB combination
Study: 25012498
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system inhibition (RASI) with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Study: 19776651
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment based on conventional laboratory parameters
Study: 10787068
Drug: Dextromethorphan 10
Normalized name: DEXTROMETHORPHAN 10MG CHEWABLE TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 10 mg IM
Study: 10787068
Drug: Dextromethorphan 20
Normalized name: dextromethorphan 20 mg/15 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 20 mg IM
Study: 10787068
Drug: Dextromethorphan 40
Normalized name: guaifenesin/dextromethorphan 400 mg-20 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 40 mg IM
Study: 10787068
Drug: Control (Chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Chlorpheniramine maleate 20 mg IM)
Study: 6148960
Drug: xamoterol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 0.1 mg/kg
Study: 30656171
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg per night and nocturnal splint
Study: 30656171
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg per night, exercises, and nocturnal splint
Study: 25305703
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1800 mg/day initiated within 24 hours after PCI
Study: 20579863
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Pycnogenol a day
Study: 20579863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pycnogenol and elastic stockings
Study: 16534182
Drug: Pitavastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (1 mg/day, n = 15)
Study: 1854026
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with 5 micrograms/mL epinephrine
Study: 6337670
Drug: Anal dilator
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anal dilator (no. 2) twice daily for 3 weeks
Study: 26852743
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management (ongoing therapy)
Study: 26852743
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management with treatment crossover to endoscopic sinus surgery (ESS)